<?xml version='1.0' encoding='utf-8'?>
<document id="29191560"><sentence text="MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia." /><sentence text="In 2009 the U" /><sentence text="S" /><sentence text=" Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD)"><entity charOffset="66-80" id="DDI-PubMed.29191560.s4.e0" text="metoclopramide" /><entity charOffset="82-85" id="DDI-PubMed.29191560.s4.e1" text="MCP" /><pair ddi="false" e1="DDI-PubMed.29191560.s4.e0" e2="DDI-PubMed.29191560.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29191560.s4.e0" e2="DDI-PubMed.29191560.s4.e1" /></sentence><sentence text=" In this study, we developed a multi-step biomedical informatics screening (MSBIS) approach leveraging publicly available bioactivity and drug safety data to identify concomitant drugs that mitigate the risks of MCP-induced TD"><entity charOffset="212-214" id="DDI-PubMed.29191560.s5.e0" text="MCP" /></sentence><sentence text=" MSBIS includes (1) TargetSearch (http://dxulab" /><sentence text="org/software) bioinformatics scoring for drug anticholinergic activity using CHEMBL bioactivity data; (2) unadjusted odds ratio (UOR) scoring for indications of TD-mitigating effects using the FDA Adverse Event Reporting System (FAERS); (3) adjusted odds ratio (AOR) re-scoring by removing the effect of cofounding factors (age, gender, reporting year); (4) logistic regression (LR) coefficient scoring for confirming the best TD-mitigating drug candidates" /><sentence text=" Drugs with increasing TD protective potential and statistical significance were obtained at each screening step" /><sentence text=" Fentanyl is identified as the most promising drug against MCP-induced TD (coefficient: -2"><entity charOffset="1-9" id="DDI-PubMed.29191560.s9.e0" text="Fentanyl" /><entity charOffset="59-66" id="DDI-PubMed.29191560.s9.e1" text="MCP" /><pair ddi="false" e1="DDI-PubMed.29191560.s9.e0" e2="DDI-PubMed.29191560.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29191560.s9.e0" e2="DDI-PubMed.29191560.s9.e1" /></sentence><sentence text="68; p-value&lt;0" /><sentence text="01)" /><sentence text=" The discovery is supported by clinical reports that patients fully recovered from MCP-induced TD after fentanyl-induced general anesthesia"><entity charOffset="104-112" id="DDI-PubMed.29191560.s12.e0" text="fentanyl" /><entity charOffset="83-90" id="DDI-PubMed.29191560.s12.e1" text="MCP" /><pair ddi="false" e1="DDI-PubMed.29191560.s12.e1" e2="DDI-PubMed.29191560.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29191560.s12.e1" e2="DDI-PubMed.29191560.s12.e0" /></sentence><sentence text=" Loperamide is identified as a potent mitigating drug against a broader range of drug-induced movement disorders through pharmacokinetic modifications"><entity charOffset="1-11" id="DDI-PubMed.29191560.s13.e0" text="Loperamide" /></sentence><sentence text=" Using drug-induced TD as an example, we demonstrated that MSBIS is an efficient in silico tool for unknown drug-drug interaction detection, drug repurposing, and combination therapy design" /><sentence text="" /></document>